
## Lixin Zhu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1391176/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multi-kingdom microbiota analyses identify bacterial–fungal interactions and biomarkers of colorectal cancer across cohorts. Nature Microbiology, 2022, 7, 238-250.	13.3	99
2	IBD Subtype-Regulators IFNG and GBP5 Identified by Causal Inference Drive More Intense Innate Immunity and Inflammatory Responses in CD Than Those in UC. Frontiers in Pharmacology, 2022, 13, 869200.	3.5	2
3	Microbial multidimensional signature assessment reveals microbial SNVs as the superior nonâ€invasive biomarkers for early detection of colorectal cancer. FASEB Journal, 2022, 36, .	0.5	0
4	Altered gut microbiome structure and its association with inflammation markers in patients with Crohn's disease in comparison to healthy siblings. FASEB Journal, 2022, 36, .	0.5	0
5	Role of GBP5 in NLRP3 inflammasome mediated intestinal inflammation in Crohn's disease. FASEB Journal, 2022, 36, .	0.5	0
6	The Proinflammatory Role of Guanylate-Binding Protein 5 in Inflammatory Bowel Diseases. Frontiers in Microbiology, 2022, 13, .	3.5	6
7	Dr <i>AFC</i> : drug repositioning through anti-fibrosis characteristic. Briefings in Bioinformatics, 2021, 22, .	6.5	5
8	Adverse Outcomes Associated With Corticosteroid Use in Critical COVID-19: A Retrospective Multicenter Cohort Study. Frontiers in Medicine, 2021, 8, 604263.	2.6	10
9	Altered gut microbiome in FUT2 lossâ€ofâ€function mutants in support of personalized medicine for inflammatory bowel diseases. FASEB Journal, 2021, 35, .	0.5	0
10	Fusobacterium nucleatum , a reproducible microbial marker for CRC prescreening. FASEB Journal, 2021, 35, .	0.5	0
11	Identification of microbial markers across populations in early detection of colorectal cancer. Nature Communications, 2021, 12, 3063.	12.8	109
12	Role of Guanylateâ€binding Protein 5 in Colonic Inflammation. FASEB Journal, 2021, 35, .	0.5	0
13	Comprehensive microbiota alterations in IBD and improved diagnostic accuracy for IBD using multiâ€kingdom microbial features. FASEB Journal, 2021, 35, .	0.5	0
14	Gastrointestinal sequelae 90 days after discharge for COVID-19. The Lancet Gastroenterology and Hepatology, 2021, 6, 344-346.	8.1	80
15	Female serotonin transporterâ€knockout rat: A potential model of irritable bowel syndrome. FASEB Journal, 2021, 35, e21701.	0.5	12
16	Editorial: Microbiome in IBD: From Composition to Therapy. Frontiers in Pharmacology, 2021, 12, 721992.	3.5	0
17	Role of gut microbiota in functional constipation. Gastroenterology Report, 2021, 9, 392-401.	1.3	53
18	Altered gut microbiome in FUT2 loss-of-function mutants in support of personalized medicine for inflammatory bowel diseases. Journal of Genetics and Genomics, 2021, 48, 771-780	3.9	21

#	Article	IF	CITATIONS
19	Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. Physiological Genomics, 2021, 53, 336-348.	2.3	17
20	The roles of Qishen granules recipes, Qingre Jiedu, Wenyang Yiqi and Huo Xue, in the treatment of heart failure. Journal of Ethnopharmacology, 2020, 249, 112372.	4.1	13
21	Moesin, an Ezrin/Radixin/Moesin Family Member, Regulates Hepatic Fibrosis. Hepatology, 2020, 72, 1073-1084.	7.3	20
22	Risk factors for the critical illness in SARS-CoV-2 infection: a multicenter retrospective cohort study. Respiratory Research, 2020, 21, 277.	3.6	8
23	Secreted phosphoglucose isomerase is a novel biomarker of nonalcoholic fatty liver in mice and humans. Biochemical and Biophysical Research Communications, 2020, 529, 1101-1105.	2.1	3
24	Melatonin ameliorates necrotizing enterocolitis by preventing Th17/Treg imbalance through activation of the AMPK/SIRT1 pathway. Theranostics, 2020, 10, 7730-7746.	10.0	50
25	Tu1257 THE IMPACT OF FUT2 DEFICIENCY ON THE GUT MICROBIOME IN INFLAMMATORY BOWEL DISEASES. Gastroenterology, 2020, 158, S-1034.	1.3	0
26	Tu1252 DAMP MOLECULES NMI AND IFP35 MAY MEDIATE EARLY INFLAMMATORY EVENTS IN THE PATHOGENESIS OF INFLAMMATORY BOWEL DISEASES. Gastroenterology, 2020, 158, S-1033.	1.3	0
27	Su1092 CAUSAL INFERENCE ANALYSIS OF THE TRANSCRIPTOME IDENTIFIED DIFFERENTIAL INNATE IMMUNITY AND INFLAMMATORY PATHWAY BETWEEN CROHN'S DISEASE AND ULCERATIVE COLITIS. Gastroenterology, 2020, 158, S-507.	1.3	0
28	Mo1463 ANALYSIS AND APPLICATION OF KEYSTONE SPECIES IN NONALCOHOLIC FATTY LIVER DISEASE BASED ON CAUSAL INFERENCE AND DYNAMIC INTERVENTION MODELING. Gastroenterology, 2020, 158, S-1412-S-1413.	1.3	1
29	Non-febrile COVID-19 patients were common and often became critically ill: a retrospective multicenter cohort study. Critical Care, 2020, 24, 314.	5.8	3
30	The Response of the Gut Microbiota to Dietary Changes in the First Two Years of Life. Frontiers in Pharmacology, 2020, 11, 334.	3.5	29
31	Enteric involvement in hospitalised patients with COVID-19 outside Wuhan. The Lancet Gastroenterology and Hepatology, 2020, 5, 534-535.	8.1	128
32	Identification of Key Factors in Cardiomyocyte Development by Single ell Transcriptome Analysis. FASEB Journal, 2020, 34, 1-1.	0.5	0
33	Metaâ€Analysis Reveals Gut Microbial Signatures in Colorectal Adenoma and A Link with Secondary Bile Acid Conversion. FASEB Journal, 2020, 34, 1-1.	0.5	0
34	FUT2 deficiency may influence the pathogenesis of inflammatory bowel diseases through gut microbiome. FASEB Journal, 2020, 34, 1-1.	0.5	0
35	NMI and IFP35 are key DAMP molecules in inflammatory bowel diseases. FASEB Journal, 2020, 34, 1-1.	0.5	0
36	In silico design of novel proton-pump inhibitors with reduced adverse effects. Frontiers of Medicine, 2019, 13, 277-284.	3.4	1

#	Article	IF	CITATIONS
37	317 – Gut Microbiota Contributes to Promoting Secondary Bile Acid Biosynthesis in Nafld Pathogenesis. Gastroenterology, 2019, 156, S-1190-S-1191.	1.3	0
38	Su1554 – Causal Inference Reveals that Clostridiales Species are Keystone Species in Nafld Pathogenesis. Gastroenterology, 2019, 156, S-1296.	1.3	0
39	Su1542 – Keystone Species in the Pathogenesis of Non-Alcoholic Fatty Liver Disease. Gastroenterology, 2019, 156, S-1293.	1.3	0
40	The milk-based diet of infancy and the gut microbiome. Gastroenterology Report, 2019, 7, 246-249.	1.3	11
41	Interactions of bile acids and the gut microbiota: learning from the differences in <i>Clostridium difficile</i> infection between children and adults. Physiological Genomics, 2019, 51, 218-223.	2.3	16
42	Difference in Pathomechanism Between Crohn's Disease and Ulcerative Colitis Revealed by Colon Transcriptome. Inflammatory Bowel Diseases, 2019, 25, 722-731.	1.9	22
43	Keystone Species in the Pathogenic Process of NAFLD. FASEB Journal, 2019, 33, 496.40.	0.5	2
44	Gut microbiota contributes to the distinction between two traditional Chinese medicine syndromes of ulcerative colitis. World Journal of Gastroenterology, 2019, 25, 3242-3255.	3.3	37
45	Gut bacteria contributes to NAFLD pathogenesis by promoting secondary bile acids biosynthesis. FASEB Journal, 2019, 33, 126.4.	0.5	2
46	New strategy of drug repositioning through antiâ€fibrosis characteristic. FASEB Journal, 2019, 33, 670.17.	0.5	0
47	The Roles of Qishen Granules Recipes, Qingre Jiedu, Wenyang Yiqi and Huo Xue, in the Treatment of Heart Failure. FASEB Journal, 2019, 33, 818.3.	0.5	1
48	Bile Acids and the Gut Microbiome as Potential Targets for NAFLD Treatment. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67, 3-5.	1.8	12
49	Anemia in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67, 351-355.	1.8	19
50	In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2018, 16, 438-446.e1.	4.4	56
51	Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut, 2018, 67, 1881-1891.	12.1	438
52	Genomics Approach of the Natural Product Pharmacology for High Impact Diseases. International Journal of Genomics, 2018, 2018, 1-2.	1.6	4
53	Editorial: Herbal Medicine on High Impact Disease: The Current Progress and Application. Current Pharmaceutical Design, 2018, 23, 5075-5076.	1.9	1
54	Gut microbiome may contribute to insulin resistance and systemic inflammation in obese rodents: a meta-analysis. Physiological Genomics, 2018, 50, 244-254.	2.3	198

#	Article	IF	CITATIONS
55	Saturated long-chain fatty acid-producing bacteria contribute to enhanced colonic motility in rats. Microbiome, 2018, 6, 107.	11.1	92
56	Role of Paraoxonase 1 as an Antioxidant in Nonalcoholic Steatohepatitis. , 2018, , 15-20.		1
57	Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease. Current Pharmaceutical Design, 2018, 23, 5136-5162.	1.9	21
58	Upregulation of non-canonical Wnt ligands and oxidative glucose metabolism in NASH induced by methionine-choline deficient diet. Trends in Cell & Molecular Biology, 2018, 13, 47-56.	0.5	7
59	Sequencing the gut metagenome as a noninvasive diagnosis for advanced nonalcoholic steatohepatitis. Hepatology, 2017, 66, 2080-2083.	7.3	13
60	Hepatic Flavin Monooxygenase 3 (FMO3) is Highly Up Regulated in Nonalcoholic Fatty Liver Disease (NAFLD). Gastroenterology, 2017, 152, S1156-S1157.	1.3	0
61	Suppressed Hepatic Bile Acid Signaling Despite Elevated Production of Primary and Secondary Bile Acids in NAFLD. Gastroenterology, 2017, 152, S1068.	1.3	7
62	High-Fat Diet Increases Clostridium Clusters XIVa in Obese Rodents: A Meta-Analysis. Gastroenterology, 2017, 152, S1012.	1.3	4
63	Multipronged Therapeutic Effects of Chinese Herbal Medicine Qishenyiqi in the Treatment of Acute Myocardial Infarction. Frontiers in Pharmacology, 2017, 8, 98.	3.5	30
64	Drugs and Targets in Fibrosis. Frontiers in Pharmacology, 2017, 8, 855.	3.5	77
65	Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment of non-alcoholic fatty liver disease. Oncotarget, 2017, 8, 27820-27838.	1.8	55
66	Systematic transcriptome analysis reveals elevated expression of alcoholâ€metabolizing genes in <scp>NAFLD</scp> livers. Journal of Pathology, 2016, 238, 531-542.	4.5	40
67	Gut microbiota produce alcohol and contribute to NAFLD. Gut, 2016, 65, 1232-1232.	12.1	42
68	1052 D-Amino Acids as a Novel Link between Gut Microbiota and Non-Alcoholic Fatty Liver Disease. Gastroenterology, 2016, 150, S1056.	1.3	0
69	Mo1521 Transcriptional Regulation of Paraoxonase 1 in Pediatric NAFLD Livers. Gastroenterology, 2016, 150, S714.	1.3	0
70	Su1857 Pathological Similarities and Differences Between Crohn's Disease and Ulcerative Colitis Revealed by Systematic Transcriptome Analysis. Gastroenterology, 2016, 150, S571.	1.3	0
71	Connection Map for Compounds (CMC): A Server for Combinatorial Drug Toxicity and Efficacy Analysis. Journal of Chemical Information and Modeling, 2016, 56, 1615-1621.	5.4	10
72	In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. Gastroenterology, 2016, 151, 1141-1154.e9.	1.3	100

#	Article	IF	CITATIONS
73	bSiteFinder, an improved protein-binding sites prediction server based on structural alignment: more accurate and less time-consuming. Journal of Cheminformatics, 2016, 8, 38.	6.1	15
74	Pathogenesis of nonalcoholic steatohepatitis. Cellular and Molecular Life Sciences, 2016, 73, 1969-1987.	5.4	151
75	Gut Microbiota of Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2016, 61, 1268-1281.	2.3	46
76	Potassium channel KCNJ15 is required for histamine-stimulated gastric acid secretion. American Journal of Physiology - Cell Physiology, 2015, 309, C264-C270.	4.6	15
77	Editorial (Thematic Issue: From Multiple Hits to Multiple Therapeutic Targets of Non-alcoholic Fatty) Tj ETQq1 1	0.7 <u>8</u> 4314 2.1	rg&T /Overlo
78	Systematic Toxicity Mechanism Analysis of Proton Pump Inhibitors: An <i>In Silico</i> Study. Chemical Research in Toxicology, 2015, 28, 419-430.	3.3	15
79	Novel pathway for iron deficiency in pediatric non-alcoholic steatohepatitis. Clinical Nutrition, 2015, 34, 549-556.	5.0	15
80	Su1800 Systematic Analysis of NAFLD Transcriptome Revealed Elevated Expression of Alcohol Metabolizing Genes in Mild and Severe NAFLD Livers. Gastroenterology, 2015, 148, S-1054.	1.3	0
81	137 Overexpression of Bile Acid Synthesis Genes in Pediatric NASH. Gastroenterology, 2015, 148, S-36.	1.3	0
82	Induction of CYP2E1 in non-alcoholic fatty liver diseases. Experimental and Molecular Pathology, 2015, 99, 677-681.	2.1	52
83	Gut microbiome and nonalcoholic fatty liver diseases. Pediatric Research, 2015, 77, 245-251.	2.3	123
84	Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers. Pathology, 2015, 47, 341-348.	0.6	24
85	Restoration of Na+/H+ exchanger NHE3-containing macrocomplexes ameliorates diabetes-associated fluid loss. Journal of Clinical Investigation, 2015, 125, 3519-3531.	8.2	36
86	Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease. Current Drug Targets, 2015, 16, 1301-1314.	2.1	79
87	Increased Insulin Resistance by Dextran Sulfate Sodium is Associated with Increased Dâ€Amino Acids and Lipopolysaccharides in Rat. FASEB Journal, 2015, 29, 848.1.	0.5	0
88	Dextran Sulfate Sodium Enhances High Fat Diet Induced Insulin Resistance in Rat. FASEB Journal, 2015, 29, 848.2.	0.5	0
89	The Stereoselectivity of <scp>CYP</scp> 2C19 on R―and Sâ€isomers of Proton Pump Inhibitors. Chemical Biology and Drug Design, 2014, 83, 610-621.	3.2	5
90	Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1292-1298.	2.8	57

Lixin Zhu

#	Article	IF	CITATIONS
91	Distribution dynamics and functional importance of NHERF1 in regulation of Mrp-2 trafficking in hepatocytes. American Journal of Physiology - Cell Physiology, 2014, 307, C727-C737.	4.6	14
92	Su1908 Potassium Channel KCNJ15 Is Required for Histamine Stimulated Gastric Acid Secretion. Gastroenterology, 2014, 146, S-498.	1.3	0
93	Potassium Channels: Structures, Diseases, and Modulators. Chemical Biology and Drug Design, 2014, 83, 1-26.	3.2	77
94	Structural changes in the gut microbiome of constipated patients. Physiological Genomics, 2014, 46, 679-686.	2.3	271
95	Tu1138 Genes of Alcohol Metabolism in Patients With Simple Steatosis and NASH. Gastroenterology, 2014, 146, S-763-S-764.	1.3	1
96	Tu2017 Non-Transferrin Bound Iron Transporter ZIP 14 in the Liver of Pediatric Non-Alcoholic Steatohepatitis Patients. Gastroenterology, 2014, 146, S-900.	1.3	0
97	Paraoxonase 1 and oxidative stress in paediatric nonâ€alcoholic steatohepatitis. Liver International, 2014, 34, 110-117.	3.9	30
98	Novel pathway for iron deficiency in pediatric nonâ€alcoholic steatohepatitis (1042.1). FASEB Journal, 2014, 28, 1042.1.	0.5	1
99	Potassium channel KCNJ15 plays a critical role in gastric acid secretion (904.1). FASEB Journal, 2014, 28, 904.1.	0.5	0
100	Inhibition of lysosomal enzyme activities by proton pump inhibitors. Journal of Gastroenterology, 2013, 48, 1343-1352.	5.1	41
101	Tu1011 Serum Endotoxin Is Not Associated With Pediatric Non-Alcoholic Steatohepatitis. Gastroenterology, 2013, 144, S-1031.	1.3	0
102	Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology, 2013, 57, 601-609.	7.3	1,321
103	398 D-Amino Acid Oxidase Gene Expression in Non-Alcoholic Steatohepatitis. Gastroenterology, 2013, 144, S-77.	1.3	0
104	Reaction of Proton Pump Inhibitors With Model Peptides Results in Novel Products. Journal of Pharmacological Sciences, 2013, 122, 213-222.	2.5	6
105	Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism. FASEB Journal, 2013, 27, 52.3.	0.5	0
106	390 Inhibition of Lysosomal Enzyme Activities by Proton Pump Inhibitors. Gastroenterology, 2012, 142, S-86.	1.3	0
107	Effect of Dietary Advanced Glycation End Products on Mouse Liver. PLoS ONE, 2012, 7, e35143.	2.5	81
108	Systematic Analysis of the Gene Expression in the Livers of Nonalcoholic Steatohepatitis: Implications on Potential Biomarkers and Molecular Pathological Mechanism. PLoS ONE, 2012, 7, e51131.	2.5	17

#	Article	IF	CITATIONS
109	Elevated Paraoxonase 1 (PON1) Activity in Pediatric Non-Alcoholic Steatohepatitis (NASH) Livers. Gastroenterology, 2011, 140, S-702.	1.3	0
110	Rab27b Localizes to the Tubulovesicle Membranes of Gastric Parietal Cells and Regulates Acid Secretion. Gastroenterology, 2011, 140, 868-878.e2.	1.3	16
111	Upregulation of Hemoglobin Expression by Oxidative Stress in Hepatocytes and Its Implication in Nonalcoholic Steatohepatitis. PLoS ONE, 2011, 6, e24363.	2.5	101
112	Paraoxonase gene expression in patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2011, 17, S65.	1.9	0
113	Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis. Metabolism: Clinical and Experimental, 2011, 60, 1001-1011.	3.4	59
114	A Rab11a-enriched subapical membrane compartment regulates a cytoskeleton-dependent transcytotic pathway in secretory epithelial cells of the lacrimal gland. Journal of Cell Science, 2011, 124, 3503-3514.	2.0	20
115	Phosphorylation of radixin regulates cell polarity and Mrp-2 distribution in hepatocytes. American Journal of Physiology - Cell Physiology, 2011, 300, C416-C424.	4.6	38
116	Acid secretion-associated translocation of KCNJ15 in gastric parietal cells. American Journal of Physiology - Renal Physiology, 2011, 301, G591-G600.	3.4	24
117	A possible mechanism for ezrin to establish epithelial cell polarity. American Journal of Physiology - Cell Physiology, 2010, 299, C431-C443.	4.6	23
118	243 Distribution Dynamics of Radixin and NHERF-1 on Regulation of MRP-2 Trafficking in Hepatocytes. Gastroenterology, 2010, 138, S-782.	1.3	0
119	Apical Recycling of the Gastric Parietal Cell H,K-ATPase. Annual Review of Physiology, 2010, 72, 273-296.	13.1	61
120	Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis. PLoS ONE, 2010, 5, e9570.	2.5	146
121	Novel insights of the gastric gland organization revealed by chief cell specific expression of moesin. American Journal of Physiology - Renal Physiology, 2009, 296, G185-G195.	3.4	17
122	Teaching glycoproteins with a classical paper: Knowledge and methods in the course of an exciting discovery. Biochemistry and Molecular Biology Education, 2008, 36, 336-340.	1.2	2
123	Comparative study of ezrin phosphorylation among different tissues: more is good; too much is bad. American Journal of Physiology - Cell Physiology, 2008, 295, C192-C202.	4.6	22
124	High turnover of ezrin T567 phosphorylation: conformation, activity, and cellular function. American Journal of Physiology - Cell Physiology, 2007, 293, C874-C884.	4.6	69
125	gp130 dimerization in the absence of ligand: Preformed cytokine receptor complexes. Biochemical and Biophysical Research Communications, 2006, 346, 649-657.	2.1	53
126	Cellular Localization and Stimulation-Associated Distribution Dynamics of Syntaxin-1 and Syntaxin-3 in Gastric Parietal Cells. Traffic, 2005, 6, 654-666.	2.7	19

Lixin Zhu

#	Article	IF	CITATIONS
127	Ezrin oligomers are the membrane-bound dormant form in gastric parietal cells. American Journal of Physiology - Cell Physiology, 2005, 288, C1242-C1254.	4.6	33
128	Phosphorylation of ezrin on threonine 567 produces a change in secretory phenotype and repolarizes the gastric parietal cell. Journal of Cell Science, 2005, 118, 4381-4391.	2.0	55
129	Gastrointestinal Consequences of Discharged COVID-19 Patients: A Multicenter Cohort Study. SSRN Electronic Journal, 0, , .	0.4	Ο
130	Upregulation of non-canonical Wnt ligands and oxidative glucose metabolism in NASH induced by methionine-choline-deficient diet. Trends in Cell & Molecular Biology, 0, 22, 47.	0.5	12